Russia’s focus on domestic pharma production could shield it from sanctions’ effects
Pharmaceutical Technology
JULY 4, 2022
Pfizer (New York, New York) has announced that it will not begin any new clinical trials in Russia and will halt recruitment in trials that are underway in Russia. Thermo Fisher states on its website that “Given the ongoing conflict, we have paused sales and manufacturing operations in Russia and Belarus.
Let's personalize your content